Thomas A Puchalski
Overview
Explore the profile of Thomas A Puchalski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parasrampuria D, Bandekar R, Puchalski T
Drug Discov Today
. 2020 Jul;
25(10):1855-1864.
PMID: 32693162
Increasingly, new drug development by major pharmaceutical companies relies on in-licensing of innovative therapies. Often there are limited data accompanying these novel entities. By focusing on scientific principles and generating...
2.
Xu C, Han C, Marini J, Ford J, Marciniak S, Lopez Jr M, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
3(4):328-34.
PMID: 27128840
Siltuximab, a monoclonal antibody (mAb) against interleukin (IL-6), is under development by Janssen Research & Development, LLC. During early clinical development, siltuximab was produced in a murine Sp2/0 myeloma cell...
3.
Mayer C, Xie L, Bandekar R, Qi M, van de Velde H, Reddy M, et al.
Cancer Chemother Pharmacol
. 2015 Mar;
75(5):1037-45.
PMID: 25784388
Purpose: Siltuximab is a monoclonal antibody that binds to interleukin (IL)-6 with high affinity and specificity; C-reactive protein (CRP) is an acute-phase protein induced by IL-6. CRP suppression is an...
4.
Orlowski R, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, et al.
Am J Hematol
. 2014 Oct;
90(1):42-9.
PMID: 25294016
We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients with relapsed/refractory multiple myeloma in a...
5.
van Rhee F, Wong R, Munshi N, Rossi J, Ke X, Fossa A, et al.
Lancet Oncol
. 2014 Jul;
15(9):966-74.
PMID: 25042199
Background: Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease....
6.
Brana I, Calles A, LoRusso P, Yee L, Puchalski T, Seetharam S, et al.
Target Oncol
. 2014 Jun;
10(1):111-23.
PMID: 24928772
C-C chemokine ligand 2 (CCL2) stimulates tumor growth, metastasis, and angiogenesis. Carlumab, a human IgG1κ anti-CCL2 mAb, has shown antitumor activity in preclinical and clinical trials. We conducted a first-in-human...
7.
Angevin E, Tabernero J, Elez E, Cohen S, Bahleda R, Van Laethem J, et al.
Clin Cancer Res
. 2014 Feb;
20(8):2192-204.
PMID: 24563479
Purpose: This phase I/II study evaluated safety, efficacy, and pharmacokinetics of escalating, multiple doses of siltuximab, a chimeric anti-interleukin (IL)-6 monoclonal antibody derived from a new Chinese hamster ovary (CHO)...
8.
Han C, McIntosh T, Geist B, Jiao T, Puchalski T, Goldberg K, et al.
AAPS J
. 2013 Nov;
16(1):125-8.
PMID: 24281691
A parallel study design with a large number of subjects has been a typical path for pharmacokinetic (PK) biocomparability assessment of biotherapeutics with long half-lives and immunogenic propensity, for example,...
9.
Thomas S, Suvorov A, Noens L, Rukavitsin O, Fay J, Wu K, et al.
Cancer Chemother Pharmacol
. 2013 Oct;
73(1):35-42.
PMID: 24149943
Purpose: A phase 1 study evaluated the QTc prolongation potential of siltuximab, a chimeric, anti-interleukin-6 mAb, in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or...
10.
Fetterly G, Aras U, Meholick P, Takimoto C, Seetharam S, McIntosh T, et al.
J Clin Pharmacol
. 2013 Jul;
53(10):1020-7.
PMID: 23878055
The chemokine ligand 2 (CCL2) promotes angiogenesis, tumor proliferation, migration, and metastasis. Carlumab is a human IgG1κ monoclonal antibody with high CCL2 binding affinity. Pharmacokinetic/pharmacodynamic data from 21 cancer patients...